Blueprint Medicines (BPMC) PT Raised to $90 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 21 | New: 12
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 21 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $90.00 (from $85.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $465 at Cantor Fitzgerald
- Westpac Banking Corp. (WBC:AU) (WBK) PT Lowered to AUD41.50 at UBS
- Amgen (AMGN) PT Raised to $470 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
